Get To Know Us

Bill Baumel

Bill Baumel

Board Member

Bill Baumel is a seasoned venture capitalist who spent more than 20 years working in Silicon Valley before starting the Ohio Innovation Fund (OIF) as Managing Director. His investment areas include big data, cybersecurity, biopharma, and medtech, and his past exits have resulted in five IPOs and 10+ major acquisitions by Dell, SAP, Medtronic, Intuit, Stryker, and others, for which he was recognized as one of the Venture 100 Top VCs based on exits. At OIF, Bill works with Ohio-based entrepreneurs to rapidly scale their companies and drive the growth of Ohio’s entrepreneurial ecosystem. Co-investors/partners of OIF investments include Sanofi, Genentech, Cardinal Health, Microsoft and Facebook. Bill holds a bachelor’s degree in business from The Ohio State University, and an MBA with high distinction from the University of Michigan.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.